Soluble and cleaved forms of the urokinase-receptor: degradation products or active molecules?

被引:90
作者
Montuori, N
Visconte, V
Rossi, G
Ragno, P
机构
[1] CNR, IEOS, I-80131 Naples, Italy
[2] Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, Naples, Italy
关键词
urokinase; receptor; uPAR; suPAR; cleaved uPAR; cancer;
D O I
10.1160/TH04-09-0580
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The urokinase-mediated plasminogen activation (PA) system is involved in many physiological and pathological events that include cell migration and tissue remodelling, such as embryogenesis, ovulation, inflammation, wound healing, angiogenesis, and tumor invasion and metastasis. The urokinase receptor (uPAR) is a key molecule of this system and can bind extracellular and cell membrane molecules such as urokinase (uPA),vitronectin (VN), integrins and chemotaxis receptors. These multiple interactions can be modulated by the shedding or the cleavage of the cell membrane receptor. Indeed, cleaved forms of uPAR, lacking the N-terminal DI domain, have been detected on the surface of cells and in tissues, while soluble forms have been found in biological fluids. Cleaved and soluble forms could represent the intermediary products of the uPAR metabolism or active molecules with precise and distinct functional roles. Here,we review the data concerning the in vitro and in vivo identification of these uPAR forms, their origin and functions, and the role that uPAR shedding and cleavage could play in biological processes.
引用
收藏
页码:192 / 198
页数:7
相关论文
共 95 条
  • [1] Andolfo A, 2002, THROMB HAEMOSTASIS, V88, P298
  • [2] The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin:: Implications for antiangiogenic strategies
    Bajou, K
    Masson, V
    Gerard, RD
    Schmitt, PM
    Albert, V
    Praus, M
    Lund, LR
    Frandsen, TL
    Brunner, N
    Dano, K
    Fusenig, NE
    Weidle, U
    Carmeliet, G
    Loskutoff, D
    Collen, D
    Carmeliet, P
    Foidart, JM
    Noël, AS
    [J]. JOURNAL OF CELL BIOLOGY, 2001, 152 (04) : 777 - 784
  • [3] Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization
    Bajou, K
    Noël, A
    Gerard, RD
    Masson, V
    Brunner, N
    Holst-Hansen, C
    Skobe, M
    Fusenig, NE
    Carmeliet, P
    Collen, D
    Foidart, JM
    [J]. NATURE MEDICINE, 1998, 4 (08) : 923 - 928
  • [4] Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G
    Beaufort, N
    Leduc, D
    Rousselle, JC
    Magdolen, V
    Luther, T
    Namane, A
    Chignard, M
    Pidard, D
    [J]. JOURNAL OF IMMUNOLOGY, 2004, 172 (01) : 540 - 549
  • [5] Domain interplay in the urokinase receptor - Requirement for the third domain in high affinity ligand binding and demonstration of ligand contact sites in distinct receptor domains
    Behrendt, N
    Ronne, E
    Dano, K
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (37) : 22885 - 22894
  • [6] A urokinase receptor-associated protein with specific collagen binding properties
    Behrendt, N
    Jensen, ON
    Engelholm, LH
    Mortz, E
    Mann, M
    Dano, K
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (03) : 1993 - 2002
  • [7] BEHRENDT N, 1991, J BIOL CHEM, V266, P7842
  • [8] BEHRINGER RP, 1993, NONLINEAR SCI TODAY, V3, P1
  • [9] uPAR: A versatile signalling orchestrator
    Blasi, F
    Carmeliet, P
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2002, 3 (12) : 932 - 943
  • [10] UROKINASE PLASMINOGEN-ACTIVATOR RECEPTOR, BETA-2-INTEGRINS, AND SRC-KINASES WITHIN A SINGLE RECEPTOR COMPLEX OF HUMAN MONOCYTES
    BOHUSLAV, J
    HOREJSI, V
    HANSMANN, C
    STOCKL, J
    WEIDLE, UH
    MAJDIC, O
    BARTKE, I
    KNAPP, W
    STOCKINGER, H
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1995, 181 (04) : 1381 - 1390